
- 1,020 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
eBook - ePub
A Comprehensive Guide to Toxicology in Nonclinical Drug Development
About this book
**Selected for 2026 Doody's Core Titles in Toxicology**A Comprehensive Guide to Toxicology in Nonclinical Drug Development, Third Edition is a valuable reference providing a complete understanding of all aspects of nonclinical toxicology in pharmaceutical research. This updated edition has been expanded and re-developed covering a wide-range of toxicological issues in small molecules and biologics. Topics include ADME in drug discovery, pharmacokinetics, toxicokinetics, formulations, and genetic toxicology testing. The book has been thoroughly updated throughout to reflect the latest scientific advances and includes new information on antiviral drugs, anti-diabetic drugs, immunotherapy, and a discussion on post-pandemic drug development challenges and opportunities. This is an essential and practical resource for all toxicologists involved in nonclinical testing in industry, academic, and regulatory settings.
- Provides updated, unique content not covered in one comprehensive resource, including chapters on stem cells, antiviral drugs, anti-diabetic drugs, and immunotherapy
- Includes the latest international guidelines for nonclinical toxicology in both small and large molecules
- Incorporates practical examples in order to illustrate day-to-day activities and expectations associated with working in nonclinical toxicology
Trusted by 375,005 students
Access to over 1.5 million titles for a fair monthly price.
Study more efficiently using our study tools.
Information
Table of contents
- Cover
- Front Matter
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- List of Illustrations
- List of Tables
- Chapter 1 : Introduction to Drug Development
- Chapter 2 : Critical Aspects of Integrated Nonclinical Drug Development: Concepts, Strategies, and Potential Pitfalls
- Chapter 3 : Overview of ADME Science
- Chapter 4 : Pharmacokinetics and Toxicokinetics in Drug Development
- Chapter 5 : Development of Preclinical Formulations for Toxicology Studies
- Chapter 6 : Acute, Subacute, Subchronic, and Chronic General Toxicity Testing for Preclinical Drug Development
- Chapter 7 : Genetic Toxicology Testing
- Chapter 8 : The Preparation of a Preclinical Dossier to Support an Investigational New Drug Application and First-In-Human Clinical Trial
- Chapter 9 : Developmental and Reproductive Toxicology
- Chapter 10 : Immunotoxicology Assessment in Drug Development
- Chapter 11 : Juvenile Testing to Support Clinical Trials in Pediatric Population
- Chapter 12 : Preclinical Evaluation of Carcinogenicity Using Standard-Bred and Genetically Engineered Rodent Models
- Chapter 13 : Current Strategies for Abuse Liability Assessment of New Chemical Entities
- Chapter 14 : Clinical Pathology in Nonclinical Toxicity Studies
- Chapter 15 : Best Practice in Toxicologic Pathology
- Chapter 16 : Molecular Pathology: Applications in Nonclinical Drug Development
- Chapter 17 : Biomarkers in Nonclinical Drug Development
- Chapter 18 : Biostatistics for Toxicologists
- Chapter 19 : Regulatory Toxicology
- Chapter 20 : Study Directors and Study Monitors in Drug Development Safety Studies
- Chapter 21 : Infusion Toxicology and Techniques
- Chapter 22 : Photosafety Assessment
- Chapter 23 : Preclinical Development of Monoclonal Antibodies
- Chapter 24 : Preclinical Development of Antibody–Drug Conjugates
- Chapter 25 : Nonclinical Safety Assessment of Cell and Gene Therapies
- Chapter 26 : How Gene Editing Is Changing Drug Development
- Chapter 27 : Nonclinical Development of Oncology Drugs
- Chapter 28 : Preclinical Development of Nononcogenic Drugs (Small and Large Molecules)
- Chapter 29 : Overview of the Nonclinical Development Strategies and Class Effects of Oligonucleotide-based Therapeutics
- Chapter 30 : Animal Models for Infectious Disease Vaccine Development
- Chapter 31 : Preclinical Toxicology of Vaccines1
- Chapter 32 : Safety Evaluation of Ocular Drugs
- Chapter 33 : Nonclinical Safety Assessment of Botanical Products
- Chapter 34 : Biocompatibility Evaluation of Medical Devices
- Chapter 35 : Application of Evolving New Approach Methodologies for Chemical Safety Assessment
- Chapter 36 : Use of Imaging for Preclinical Evaluation
- Index
- A
Frequently asked questions
Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn how to download books offline
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1.5 million books across 990+ topics, we’ve got you covered! Learn about our mission
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more about Read Aloud
Yes! You can use the Perlego app on both iOS and Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app
Yes, you can access A Comprehensive Guide to Toxicology in Nonclinical Drug Development by Ali S. Faqi in PDF and/or ePUB format, as well as other popular books in Medicine & Pharmaceutical, Biotechnology & Healthcare Industry. We have over 1.5 million books available in our catalogue for you to explore.